Semaglutide Shows Promising Efficacy in Resolving Non-alcoholic Steatohepatitis (NASH)
Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.
Background
Non-alcoholic Steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease (NAFLD) characterized by liver inflammation, hepatocyte ballooning, and fibrosis, which can progress to cirrhosis, liver failure, and hepatocellular carcinoma. Affecting millions globally, NASH represents a significant unmet medical need, as effective pharmacological treatments for NASH are currently limited. This global clinical trial aimed to evaluate the efficacy and safety of Semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist, in subjects diagnosed with NASH.